Lu Xu

Bayesian Inference in Physiologically-based Pharmacokinetic Modeling: Application to Aniticancer Drug Development

M. Egorin, D. D’Argenio, J. Eiseman, 2004 .

Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study.

Helen X. Chen, S. Baruchel, R. Kerbel, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach.

P. Kuebler, A. Joshi, T. Lu, 2013, Investigative ophthalmology & visual science.

Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors

S. Litwin, P. O'dwyer, A. Dorr, 2009, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics Evaluation of Mycophenolic Acid and Its Glucuronide Metabolite in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus

Z. Jiao, Xiaoyan Qiu, Ming Zhang, 2018, Therapeutic drug monitoring.

Prevention of oxaliplatin-related neurotoxicity by ω-3 PUFAs

Liping Zhang, Lu Xu, Qinghua Yao, 2020, Medicine.

Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys

Yvonne S. Lin, B. Lum, N. Modi, 2008, Cancer Chemotherapy and Pharmacology.

Physiologically-Based Pharmacokinetics and Molecular Pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and Its Active Metabolite in Tumor-Bearing Mice

David Z. D'Argenio, Julie L. Eiseman, Merrill J. Egorin, 2003, Journal of Pharmacokinetics and Pharmacodynamics.